The Technical Analyst
Medpace Holdings Inc [MEDP]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Diagnostics & Research
Medpace Holdings Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
1.68% $141.88
Last updated: 16 May 2022 @ 11:48 am
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4 773.85 mill |
| EPS: | 5.35 |
| P/E: | 26.53 |
| Earnings Date: | Jul 25, 2022 |
| SharesOutstanding: | 33.65 mill |
| Avg Daily Volume: | 0.312 mill |
| RATING 2022-05-13 |
|---|
| S- |
| Strong Buy |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.06x |
| Company: PE 26.53 | sector: PE 480.39 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| infx |
| Company: PE 26.53 | industry: PE 0.000 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$154.11 (8.62%) $12.23 |
| Date: 2022-05-16 |
| True Range Average |
|---|
|
+/- $6.72 ( +/- 4.82%) Range: 132.81 - 146.25 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-06 | Ewald Stephen P | Sell | 1 000 | Employee Stock Option (Right to Buy) |
| 2022-05-06 | Ewald Stephen P | Buy | 1 000 | Common Stock |
| 2022-03-01 | Troendle August J. | Sell | 100 000 | Employee Stock Option (Right to Buy) |
| 2022-03-01 | Troendle August J. | Buy | 100 000 | Common Stock |
| 2022-02-23 | Burwig Susan E | Sell | 12 400 | Employee Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -55.31 |
| Last 100 transactions |
| Buy: 335 743 | Sell: 1 339 882 |
Forecast:
13:27 - $140.80
Live Trading Signals (every 1 min)
Forecast
1: 11:57 - $141.75
Forecast 2: 12:47 - $140.49
Forecast 3: 13:27 - $140.80
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $141.88 (1.68% ) |
| Volume | 0.0768 mill |
| Avg. Vol. | 0.312 mill |
| % of Avg. Vol | 24.57 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MEDP
267 Signals | Accuracy: 30.71% | Accuracy Buy: 32.33% | Accuracy Sell: 29.10%
Avg return buy: 0.01 % | Avg return sell: -0.07 %
$1 invested is now $1.01 or 1.19% since 20-04-22
| Date | Signal | @ | Closed | % | May 16 - 11:24 | buy | $140.04 | N/A | Active |
|---|---|---|---|---|
| May 16 - 11:23 | sell | $139.63 | $140.04 @ May 16 - 11:24 | 0.29% |
| May 16 - 11:21 | buy | $139.85 | $139.63 @ May 16 - 11:22 | -0.16% |
| May 16 - 11:15 | sell | $139.67 | $139.92 @ May 16 - 11:20 | 0.18% |
| May 16 - 11:10 | buy | $139.82 | $139.65 @ May 16 - 11:14 | -0.12% |
| May 16 - 10:35 | sell | $140.28 | $140.37 @ May 16 - 10:49 | 0.06% |
| May 16 - 10:25 | buy | $140.92 | $140.28 @ May 16 - 10:35 | -0.45% |
| May 13 - 15:36 | sell | $140.85 | $140.77 @ May 16 - 10:24 | -0.06% |
| May 13 - 15:30 | buy | $141.48 | $141.23 @ May 13 - 15:35 | -0.17% |
| May 13 - 15:20 | sell | $141.21 | $141.48 @ May 13 - 15:30 | 0.19% |
MEDP
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Latest Press Releases
2022-04-25 16:15:00 - Press Release
Medpace Holdings, Inc. Reports First Quarter 2022 Results
Cincinnati--(business wire)--medpace holdings, inc. (nasdaq: medp) (“medpace”) today announced financial results for the first quarter ended march 31, 2022. first quarter 2022 financial results revenue for the three months ended march 31, 2022 increased 27.3% to $330.9 million, compared to $260.0 million for the comparable prior-year period. on a constant currency organic basis, revenue for the first quarter of 2022 increased 28.1% compared to the first quarter of 2021. backlog as of march 31,
2022-03-23 16:32:00 - Press Release
Medpace Donation To Matthew 25: Ministries Funds Delivery Of Relief Supplies To Ukraine
Cincinnati--(business wire)--medpace (medp), a global clinical research organization (cro), has partnered with matthew 25: ministries, a humanitarian and disaster relief organization, to fund aid shipments to ukraine and surrounding areas. the contribution will facilitate shipping and distribution of critically needed aid with an estimated value above $2.5 million. it will help hundreds of thousands of people in need in ukraine and the surrounding areas. "medpace has offices in both ukraine and
2022-02-14 16:15:00 - Press Release
Medpace Holdings, Inc. Reports Fourth Quarter And Full Year 2021 Results
Cincinnati--(business wire)--medpace holdings, inc. (nasdaq: medp) (“medpace”) today announced financial results for the fourth quarter and full year ended december 31, 2021. fourth quarter and full year 2021 financial results revenue for the three months ended december 31, 2021 increased 18.8% to $308.6 million, compared to $259.7 million for the comparable prior-year period. revenue for the year ended december 31, 2021 increased 23.4% to $1,142.4 million, compared to $925.9 million for the ye
2021-02-15 16:15:00 - Press Release
Medpace Holdings, Inc. Reports Fourth Quarter And Full Year 2020 Results
Cincinnati--(business wire)--medpace holdings, inc. (nasdaq: medp) (“medpace”) today announced financial results for the fourth quarter and full year ended december 31, 2020. fourth quarter and full year 2020 financial results revenue for the three months ended december 31, 2020 increased 13.0% to $259.7 million, compared to $229.9 million for the comparable prior-year period. revenue for the year ended december 31, 2020 increased 7.5% to $925.9 million, compared to $861.0 million for the year
2020-07-27 19:30:00 - Press Release
Medpace Holdings Reports Q2 Earnings Per Share $0.64
Medpace holdings, inc. reports second quarter 2020 results.q2 gaap earnings per share $0.64.q2 revenue $205 million versus refinitiv ibes estimate of $180.5 million.q2 earnings per share estimate $0.41 -- refinitiv ibes data.sees fy 2020 gaap earnings per share $3.62 to $3.83.sees fy 2020 revenue up 2.2 to 6.9 percent.sees fy 2020 revenue $880 million to $920 million.backlog as of june 30, 2020 grew 14.6% to $1.3 billion.
Latest News
2022-04-28 14:17:36 - Zacks Investment Research
Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think " Yes "
2022-04-26 13:58:03 - Seeking Alpha
Medpace Holdings' (MEDP) CEO August Troendle on Q1 2022 Results - Earnings Call Transcript
Medpace Holdings, Inc. (NASDAQ:MEDP ) Q1 2022 Earnings Conference Call April 26, 2022 9:00 AM ET Company Participants Lauren Morris – Director-Investor Relations August Troendle – Chief Executive Officer Jesse Geiger – President Kevin Brady – Chief Financial Officer Conference Call Participants Dave Windley – Jefferies Eric Coldwell – Baird Christine Rains – William Blair Paul Knight – KeyBanc Operator Good day, ladies and gentlemen, and welcome to the Medpace First Quarter 2022 Earnings Conference Call. At this time all participants are in a listen-only mode.
2022-04-26 11:54:02 - Benzinga
Medpace Posts Better Than Expected Q1 Earnings, Lifts FYY22 Profit Outlook
Medpace Holdings Inc's (NASDAQ: MEDP) Q1 revenue increased 27.3% Y/Y to $330.9 million, beating the consensus of $327.09 million. On a constant currency organic basis, revenue increased 28.1%.
2022-04-25 18:48:25 - Zacks Investment Research
Medpace (MEDP) Q1 Earnings and Revenues Surpass Estimates
Medpace (MEDP) delivered earnings and revenue surprises of 34.13% and 1.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-04-09 07:51:48 - Seeking Alpha
Medpace Holdings: Recent Price Dislocation Buying Opportunity
Medpace Holdings is a healthy business trading at a discount to its intrinsic value. Price target $193-200.
2022-02-23 13:58:00 - Seeking Alpha
Medpace Holdings: Best Medical Diagnostic Stock For Near-Term Price Gain Say Market Makers
What do they know, how? By a community of over 100,000 world-wide information-gatherers reporting back to Market-Maker HQ trading desks.
2022-02-16 11:35:27 - Zacks Investment Research
Down 18.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Medpace (MEDP)
The heavy selling pressure might have exhausted for Medpace (MEDP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2022-02-15 13:40:04 - Seeking Alpha
Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q4 2021 Results - Earnings Call Transcript
Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q4 2021 Results - Earnings Call Transcript
2022-02-14 19:19:55 - Zacks Investment Research
Medpace (MEDP) Q4 Earnings Beat Estimates
Medpace (MEDP) delivered earnings and revenue surprises of 5.60% and 0.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
2022-02-07 16:10:11 - Zacks Investment Research
Analysts Estimate Medpace (MEDP) to Report a Decline in Earnings: What to Look Out for
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.